Skip to main content

Simon Crabb

Dr Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton in the UK. His research interests lie in the development of novel systemic treatment strategies for bladder and prostate cancers, cancer therapy resistance mechanisms, and epigenetic therapeutics. He was awarded his PhD in 2006 for research on the pre-clinical development of histone deacetylase inhibitors. This was followed by post-doctoral training as a Clinical Research Fellow at the BC Cancer Agency in Vancouver and the Cancer Research UK Centre in Southampton. Dr Crabb is the Associate Clinical Director of the Southampton Clinical Trials Unit, Deputy Director of the Southampton Experimental Cancer Medicine Centre, Chair of the Genomics England Clinical Interpretation Partnership for bladder cancer, and a member of the NCRI Bladder and Renal Group, the NCRI Prostate Group, and the Experimental Medicine Expert Review Panel for Cancer Research UK. He is a lead for early phase cancer trials. He is an active contributor to the UK academic trials portfolio in urological malignancies, including as Chief Investigator for the SPIRE, AURORA, GUSTO, MANCAN2 and ProCAID trials.


Latest contributions from Simon Crabb

Simon Crabb and Petros Grivas

08-03-2022 | ASCO GU 2022 | Conference coverage | Video

Simon Crabb and Petros Grivas share their highlights from ASCO GU

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

Simon Crabb

18-02-2022 | ASCO GU 2022 | Conference coverage | Video

ATLANTIS points to maintenance benefit of rucaparib in mUC

Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany